These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7536281)

  • 1. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
    Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
    Lung; 1995; 173(2):79-87. PubMed ID: 7536281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
    Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
    Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions.
    Daste G; Serre G; Mauduyt MA; Vincent C; Caveriviere P; Soleilhavoup JP
    Cytopathology; 1991; 2(1):19-28. PubMed ID: 1715202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinction of mesothelioma from carcinoma in pleural effusions. An immunocytochemical study on routinely processed cytoblock preparations.
    Kuhlmann L; Berghäuser KH; Schäffer R
    Pathol Res Pract; 1991 May; 187(4):467-71. PubMed ID: 1876528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N; Hasleton PS
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
    Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB
    Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Wirth PR; Legier J; Wright GL
    Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
    González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
    Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
    Maguire B; Whitaker D; Carrello S; Spagnolo D
    Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
    Mezger J; Lamerz R; Permanetter W
    J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
    Churg A
    Am J Surg Pathol; 1985 May; 9(5):360-5. PubMed ID: 2418692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
    Vortmeyer AO; Preuss J; Padberg BC; Kastendieck H; Schröder S
    Anticancer Res; 1991; 11(2):889-94. PubMed ID: 1712181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoperoxidase staining of malignant cells in pleural effusions.
    Pastormerlo M
    Pathologica; 1990; 82(1080):421-5. PubMed ID: 2284143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.
    Kwee WS; Veldhuizen RW; Golding RP; Mullink H; Stam J; Donner R; Boon ME
    Virchows Arch A Pathol Anat Histol; 1982; 397(3):287-99. PubMed ID: 6186071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A; Hjerpe A
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
    Dejmek A; Hjerpe A
    Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
    Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
    J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.